{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T23:53:59Z","timestamp":1791071639115,"version":"4.1.0"},"reference-count":61,"publisher":"Wiley","issue":"s1","license":[{"start":{"date-parts":[[2011,1,4]],"date-time":"2011-01-04T00:00:00Z","timestamp":1294099200000},"content-version":"vor","delay-in-days":3,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J of Gastro and Hepatol"],"published-print":{"date-parts":[[2011,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>There has been a recent paradigm shift in the indications and endpoints of treatment for chronic hepatitis B (CHB). Hepatitis B e antigen (HBeAg)\u2010negative disease is being increasingly recognized. Antiviral treatment for both HBeAg\u2010positive and HBeAg\u2010negative patients should aim at long\u2010term suppression of HBV DNA, with the ultimate ideal endpoint of hepatitis B surface antigen (HBsAg) seroconversion. Conventional interferon alpha (IFN\u2010\u03b1), the only agent licensed in 1991, has been superseded by pegylated IFN\u2010\u03b1. HBeAg seroconversion using pegylated IFN\u2010\u03b1 is 33%, with only 25% of HBeAg\u2010positive patients achieving undetectable HBV DNA by polymerase chain reaction (PCR) assay. Five nucleoside\/nucleotide analogues have been licensed since 1998. Lamivudine, an L\u2010nucleoside, is limited by the development of resistance in 76% of patients after 5 years of therapy. Telbivudine, another L\u2010nucleoside, is more potent than lamivudine but resistance still develops in 25% of HBeAg\u2010positive and 11% HBeAg\u2010negative patients after 2 years. Adefovir, an acyclic phosphonate, is relatively weak, but is effective against lamivudine\u2010 and telbivudine\u2010 resistant mutations, for which it should be used in combination (add\u2010on therapy) rather than substituted. Resistance to adefovir develops slowly, rising to 29% for HBeAg\u2010negative patients by year 5, but more rapidly when used alone for lamivudine\u2010resistant HBV. Currently the two first line nucleoside\/nucleotides are entecavir and tenofovir. Entecavir, a cyclopentane (D\u2010nucleoside), is very potent, with 94% of patients having undetectable HBV DNA after 5 years. Resistance develops in only 1.2% of treatment\u2010na\u00efve patients. Tenofovir, another acyclic nucleotide, is more potent with less renal toxicity compared to adefovir. It is effective against lamivudine\u2010resistant mutations when used alone. No resistance to tenofovir has been described after its use for 3 years or longer, often for patients with human immunodeficiency virus\/HBV co\u2010infection. With these current, potent antiviral agents associated with very low rates of resistance, long\u2010term HBV DNA suppression and possibly even reversal of cirrhosis can now be achieved in a proportion of patients. In addition, long\u2010term treatment with these antiviral agents is associated with a reduced risk of development of hepatocellular carcinoma.<\/jats:p>","DOI":"10.1111\/j.1440-1746.2010.06545.x","type":"journal-article","created":{"date-parts":[[2011,1,4]],"date-time":"2011-01-04T12:16:32Z","timestamp":1294143392000},"page":"138-143","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":126,"title":["Treatment of chronic hepatitis B: Evolution over two decades"],"prefix":"10.1111","volume":"26","author":[{"given":"Man\u2010Fung","family":"Yuen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching\u2010Lung","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,1,4]]},"reference":[{"key":"e_1_2_11_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)15108-2"},{"key":"e_1_2_11_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2009.05924.x"},{"key":"e_1_2_11_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2009.05784.x"},{"key":"e_1_2_11_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2009.05985.x"},{"key":"e_1_2_11_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2009.06165.x"},{"key":"e_1_2_11_7_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.34.2_Suppl.S74"},{"key":"e_1_2_11_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(88)90367-8"},{"key":"e_1_2_11_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510260536"},{"key":"e_1_2_11_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)07236-5"},{"key":"e_1_2_11_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510290312"},{"key":"e_1_2_11_12_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2001.25273"},{"key":"e_1_2_11_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(00)00094-5"},{"key":"e_1_2_11_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2006.08.021"},{"key":"e_1_2_11_15_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2005.065136"},{"key":"e_1_2_11_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22476"},{"key":"e_1_2_11_17_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.1.65"},{"key":"e_1_2_11_18_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.11.016"},{"key":"e_1_2_11_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2008.07.023"},{"key":"e_1_2_11_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2005.00603.x"},{"key":"e_1_2_11_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2007.03390.x"},{"key":"e_1_2_11_22_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-147-1-200707030-00010"},{"key":"e_1_2_11_23_2","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2009.204"},{"key":"e_1_2_11_24_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.07.008"},{"key":"e_1_2_11_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2008.10.001"},{"key":"e_1_2_11_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23190"},{"key":"e_1_2_11_27_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-008-9080-3"},{"key":"e_1_2_11_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2008.08.021"},{"key":"e_1_2_11_29_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199807093390201"},{"key":"e_1_2_11_30_2","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1177\/135965350701200816","article-title":"Long\u2010term lamivudine therapy reduces the risk of long\u2010term complications of chronic hepatitis B infection even in patients without advanced disease","volume":"12","author":"Yuen MF","year":"2007","journal-title":"Antivir. Ther."},{"key":"e_1_2_11_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(09)70056-8"},{"key":"e_1_2_11_32_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa033364"},{"key":"e_1_2_11_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.hepres.2005.02.006"},{"issue":"1","key":"e_1_2_11_34_2","first-page":"550A","article-title":"The effect of lamivudine on preventing hepatocellular carcinoma in chronic hepatitis B: a retrospective study of 2518 patients","volume":"44","author":"Eun JR","year":"2006","journal-title":"Hepatology"},{"key":"e_1_2_11_35_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe0808185"},{"key":"e_1_2_11_36_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2006.09.020"},{"key":"e_1_2_11_37_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2002-35697"},{"key":"e_1_2_11_38_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21534"},{"key":"e_1_2_11_39_2","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1177\/135965350701200109","article-title":"Adefovir dipivoxil monotherapy and combination therapy with lamivudine for the treatment of chronic hepatitis B in an Asian population","volume":"12","author":"Fung J","year":"2007","journal-title":"Antivir. Ther."},{"key":"e_1_2_11_40_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20939"},{"key":"e_1_2_11_41_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.08.079"},{"key":"e_1_2_11_42_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.03.006"},{"key":"e_1_2_11_43_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051285"},{"key":"e_1_2_11_44_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051287"},{"key":"e_1_2_11_45_2","first-page":"58","article-title":"A three\u2010year study on viral suppression and resistance profile for treatment\u2010naive CHB patients receiving continuous entecavir treatment","volume":"4","author":"Seto WK","year":"2010","journal-title":"Hepatol. Int."},{"key":"e_1_2_11_46_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23327"},{"key":"e_1_2_11_47_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02395-06"},{"key":"e_1_2_11_48_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22841"},{"key":"e_1_2_11_49_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2008.05760.x"},{"key":"e_1_2_11_50_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-009-9162-x"},{"key":"e_1_2_11_51_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2009.01146.x"},{"key":"e_1_2_11_52_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa066422"},{"key":"e_1_2_11_53_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.10.026"},{"key":"e_1_2_11_54_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2001.27563"},{"key":"e_1_2_11_55_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2008.12.019"},{"key":"e_1_2_11_56_2","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1177\/135965350901400511","article-title":"Combination of baseline parameters and on\u2010treatment hepatitis B virus DNA levels to start and continue patients with lamivudine therapy","volume":"14","author":"Yuen MF","year":"2009","journal-title":"Antivir. Ther."},{"key":"e_1_2_11_57_2","first-page":"532A","article-title":"Resistance surveillance for up to 144 weeks in HBeAg\u2010positive and HBeAg\u2010nagative hepatitis B patients treated with tenofovir DF showed no relationship between virologic breakthrough and emergence of genotypic changes in HBV polymerase","volume":"50","author":"Snow\u2010Lampart A","year":"2009","journal-title":"Hepatology"},{"key":"e_1_2_11_58_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23246"},{"key":"e_1_2_11_59_2","doi-asserted-by":"publisher","DOI":"10.1177\/135965350601100806"},{"key":"e_1_2_11_60_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23462"},{"key":"e_1_2_11_61_2","doi-asserted-by":"publisher","DOI":"10.3851\/IMP1499"},{"key":"e_1_2_11_62_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2008.03816.x"}],"container-title":["Journal of Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1440-1746.2010.06545.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1440-1746.2010.06545.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T17:55:08Z","timestamp":1694541308000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1440-1746.2010.06545.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1]]},"references-count":61,"journal-issue":{"issue":"s1","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["10.1111\/j.1440-1746.2010.06545.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1440-1746.2010.06545.x","archive":["Portico"],"relation":{},"ISSN":["0815-9319","1440-1746"],"issn-type":[{"value":"0815-9319","type":"print"},{"value":"1440-1746","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,1]]},"assertion":[{"value":"2011-01-04","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}